PDCD1 and non-small cell lung carcinoma: For example, PD-L1 expresses in at least 50% of tumor cells in patients with advanced NSCLC, only 45.2% of these patients benefited from the anti-PD-1 antibody, pembrolizumab (Garon et al., 2015).